Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lauren Dockery
Institutions:
OU Health Stephenson Cancer Center,
University of Oklahoma Health Sciences Center,
University of Oklahoma
Observed institutions:
OU Health Stephenson Cancer Center,
University of Oklahoma Health Sciences Center,
University of Oklahoma
ORCID:
0000-0002-4883-750X
Observed ORCID:
0000-0002-4883-750X
OpenAlex ID:
A5081916167
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
2024
·
Debra L. Richardson
, Julia C. F. Quintanilha
, et al.
·
Clinical Cancer Research
·
41
nab-Sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer: A phase II, open-label, single-arm, prospective, multicenter study
2024
·
Lauren Dockery
, Brian Slomovitz
, et al.
·
Gynecologic Oncology
·
2
Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
2025
·
Debra L. Richardson
, Julia C.F. Quintanilha
, et al.
·
Clinical Cancer Research
·
1
PDF
TP004/#1561 A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
2024
·
Lauren Dockery
, Fernanda Musa
, et al.
·
International Journal of Gynecological Cancer
·
1
PDF
Phase III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial carcinoma (NRG-GY026)
2026
·
Britt Erickson
, Danielle Enserro
, et al.
·
Gynecologic Oncology
Stage and histology specific tumor microbiome signatures in cervical cancer: Insights from the ORIEN cohort
2026
·
Julia Chalif
, Yogita Mehra
, et al.
·
Gynecologic Oncology
Tumoral, clinical, and environmental factors, including microbiome, immune cell infiltration and air pollution, associated with endometrial cancer recurrence
2026
·
Andrew Polio
, Ahmad Tarhini
, et al.
·
Gynecologic Oncology
Abstract 3112: Targeting chemoresistance in ovarian cancer
2026
·
Dhanamjai Penta
, Vishal Chandra
, et al.
·
Cancer Research
Sequencing of mirvetuximab soravtansine and weekly paclitaxel: Does order matter?
2025
·
Bethany Werner
, Nicole Minalt
, et al.
·
Gynecologic Oncology
Supplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
2024
·
Debra L. Richardson
, Julia C. F. Quintanilha
, et al.
Data from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
2024
·
Debra L. Richardson
, Julia C. F. Quintanilha
, et al.
Show more works
View as search
Works count:
11
Citation count:
45
H-index:
2
I10-index:
1
Year
Topic
Type